News Focus
News Focus
Followers 38
Posts 2912
Boards Moderated 0
Alias Born 06/05/2012

Re: TheHound post# 78129

Thursday, 11/13/2014 10:33:07 AM

Thursday, November 13, 2014 10:33:07 AM

Post# of 405212
I would be ambivalent regarding up-listing except for one thing; Leo's credibility is on the line. Up-listing has been mentioned previous to the appointment of Dr. Schechter to the Board. But the comments (reprinted below) in the September 2nd PR have created an expectation that up-listing is imminent.

Leo has proven time and again that our confidence in him is justified. But as more eyes are drawn to our emerging biotech enterprise, I don't want any blemishes on his record. It's been over 10 weeks since the September PR said "in the coming weeks". I hope to see a PR very soon that fulfills that promise.

Cellceutix is focused on meeting the remaining requirements necessary to uplist to a senior exchange. The Company believes that being listed on the New York Stock Exchange or NASDAQ will serve many valuable functions, including allowing large funds and institutions to invest who are otherwise not allowed to invest in OTC-listed companies, increased stock liquidity, and validating market potential for Cellceutix’s extensive pipeline. Cellceutix plans to call for a shareholder meeting to elect additional independent directors for serving on its board and audit committee in the coming weeks. - From the September 2nd PR


I'm not a big fan of uplisting right now either. - Apparition

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y